Global Orphan Drug Market Outlook 2018

Published: February 2014
No. of Pages: 213
  

The global pharmaceutical industry has been experiencing a slow growth in recent years owing to many factors such as expiration of patents, competition from generic drugs segment, exhausting pipelines, and an increasingly stringent regulatory framework. It is most likely that many blockbuster drugs would lose their exclusivity in the next 5 year horizon.

Thus, due to significant competition from generics and the current economic situation, the focus area of the pharmaceutical companies is undergoing a paradigm shift from manufacturing traditional essential medicines to investing in the new business model, which is also called orphan drugs. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs.

The major drivers for companies to increasingly invest in orphan drugs include government incentives for drug development and strong support from the FDA and EU Commission in special protocols. Inspite of pharma companies facing many obstacles in this field, this segment of orphan drugs is likely to have the potential to provide the key to recovery and stability within the market.

The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs.

"Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to global orphan drug market:

  • Global & Regional Orphan Drug Market Overview
  • Orphan Drug Designation Criteria Across Key Markets
  • Market Specific Reimbursement Policy & Regulatory Framework
  • Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country
  • Competitive Landscape

Global Orphan Drug Market Outlook 2018

Table of Contents

1. Introduction to Orphan Drugs
1.1 Orphan Drug Defined
1.2 Rising Popularity of Orphan Drugs

2. Why Shift from Non-Orphan to Orphan Drugs?
2.1 Exhausting Product Pipelines
2.2 Profitability of Orphan Drugs
2.3 Increasing R&D Investment
2.4 Role of Economic Incentives
2.5 Patent Protection & Market Exclusivity

3. Global Orphan Drug Market Outlook
3.1 Market Overview
3.2 Biological & Non-Biological Orphan Drugs
3.3 Therapeutic Segmentation
3.4 Regional Segmentation

4. US Orphan Drug Market Outlook
4.1 Orphan Drug Designation Criteria
4.2 Market Overview
4.3 Reimbursement Policy
4.4 Regulatory Framework

5. Europe Orphan Drug Market Outlook
5.1 Orphan Drug Designation Criteria
5.2 Market Overview
5.3 Reimbursement Policy
5.4 Regulatory Framework

6. Asia Orphan Drug Market Outlook
6.1 Orphan Drug Designation Criteria
6.2 Market Overview
6.3 Reimbursement Policy
6.4 Regulatory Framework

7. Global Orphan Drug Pipeline Insight by Phase, Orphan Designated Disease & Country
7.1 Clinical Phase: Research
7.2 Clinical Phase: Preclinical
7.3 Clinical Phase: Phase I
7.4 Clinical Phase:Phase I/II
7.5 Clinical Phase:Phase II
7.6 Clinical Phase:Phase II/III
7.7 Clinical Phase:Phase III
7.8 Clinical Phase:Preregistration
7.9 Clinical Phase:Registered

8. Key Issue to be Resolved
8.1 High Initial Investment
8.2 Clinical Study Hurdles
8.3 Regulatory Hurdles
8.4 Different Reimbursement Policy
8.5 Distribution Challenges

9. Competitive Landscape
9.1 Pfizer
9.2 Roche
9.3 Sanofi
9.4 Rare Disease Therapeutics
9.5 Glaxosmithkline
9.6 Merck
9.7 Novartis Pharmaceuticals
9.8 Alexion
9.9 Celgene
9.10 Biogen Idec
9.11 Eli Lilly
9.12 Bristol Myers Squibb

List of Tables

Table 2-1: Drugs Patent Expiry in 2014
Table 2-2: Drugs Patent Expiry in 2015
Table 2-3: Drugs Patent Expiry in 2016
Table 2-4: Orphan Drugs in the US and their Costs
Table 2-5: Orphan Drugs in the EU and their Costs
Table 2-6: Incentives for the Development of Orphan Drugs
Table 2-7: Orphan Drug Incentives by Country
Table 7-1: Global - Orphan Drugs in Clinical Development Phase: Research
Table 7-2: Global -Orphan Drugs in Clinical Development Phase: Preclinical
Table 7-3: Global - Orphan Drugs in Clinical Development Phase I
Table 7-4: Global - Orphan Drugs in Clinical Development Phase I/II
Table 7-5: Global - Orphan Drugs in Clinical Development Phase II
Table 7-6: Global - Orphan Drugs in Clinical Development Phase II/III
Table 7-7: Global - Orphan Drugs in Clinical Development Phase III
Table 7-8: Global - Orphan Drugs in Clinical Development Phase: Preregistration
Table 7-9: Global - Orphan Drugs in Clinical Development Phase: Registered

List of Figures

Figure 2-1: Orphan v/s Non-Orphan Drugs -Phase II to Launch Clinical Development Time
Figure 2-2: Probability of Regulatory Success of Orphan v/s Non-Orphan Drugs
Figure 3-1: Global Orphan Drugs Market Value (US$ Billion), 2012-2018
Figure 3-2: Biological & Non Biological Orphan Drug Segment (%), 2012 & 2018
Figure 3-3: Biological & Non Biological Orphan Drug Market (US$ Billion), 2012-2018
Figure 3-4: Global Orphan Drugs Market by Therapeutic Area, 2012 & 2018
Figure 3-5: Regional Markets for Orphan Drugs, 2012 & 2018
Figure 4-1: US Market for Orphan Drugs (US$ Billion), 2012-2018
Figure 4-2: US - Orphan Drug Development by Clinical Phase (%)
Figure 4-3: US - Number of Orphan Drug by Clinical Phase
Figure 5-1: European Market for Orphan Drugs (US$ Billion), 2012-2018
Figure 5-2: Europe - Orphan Drug Development by Clinical Phase (%)
Figure 5-3: Europe - Number of Orphan Drug by Clinical Phase
Figure 6-1: Asia- Orphan Drug Development by Clinical Phase (%)
Figure 6-2: Asia - Number of Orphan Drug by Clinical Phase
Figure 6-3: Japan Orphan Drug/Medical Device Designation System
Figure 6-4: Japan Orphan Drug/Device Designation Process
Figure 7-1: Global - Orphan Drug Development by Clinical Phase (%)
Figure 7-2: Global - Number of Orphan Drug by Clinical Phase
Figure 7-3: Global - Number of Orphan Drug by Clinical Phase & Region
Figure 8-1: Orphan Drug Regulatory Hurdles

Published By: Kuick Research
Product Code: Kuick Research


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:

  • Orphan Diseases Partnering Terms and Agreements

    Delivery of this report will take 1-3 days after purchase.The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements e...

  • Swedish Orphan Biovitrum AB - Product Pipeline Review - 2013

    Swedish Orphan Biovitrum AB - Product Pipeline Review - 2013 Summary Global Market Direct’s pharmaceuticals report, “Swedish Orphan Biovitrum AB - Product Pipeline Review - 2013” provides data on the Swedish Orphan Biovitrum AB’s research and d

  • Global Orphan Drug Pipeline Analysis

    In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections...

  • US Orphan Drug Pipeline Analysis

    In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections...

  • Orphan Drugs for Cancer Pipeline Analysis

    A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority...

  • Europe Orphan Drugs Pipeline Analysis

    Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles ...

  • The World Market for Orphan Drugs

    In recent years, there has been a substantial increase in the number of drugs available to treat rare (orphan) diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the m...

  • Swedish Orphan Biovitrum AB – Product Pipeline Review – 2012

    Swedish Orphan Biovitrum AB – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “Swedish Orphan Biovitrum AB - Product Pipeline Review - 2012” provides data on the Swedish Orphan Biovitrum AB’s research and d

  • Re-evaluating Pharmaceutical Pipelines - Emerging Markets, Biologics and Orphan Drugs to Shape Future Decision Making

    GBI Research, a leading business intelligence provider, has released its latest research, Re-evaluating Pharmaceutical Pipelines Emerging Markets, Biologics and Orphan Drugs to Shape Future Decision Making, which examines the key issues influencin...

  • Clinical Trials Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology

    Report SummaryClinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in OncologyGBI Research, the leading business intelligence pro...


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100